Filing Analysis
BioRestorative Therapies, Inc. received a delinquency notification from Nasdaq due to its failure to timely file its Form 10-Q for the quarter ended June 30, 2026. The company must submit a compliance plan by October 20, 2026, to avoid potential delisting.
🚩 Red Flags
- Failure to file periodic financial reports (Form 10-Q) is a primary indicator of internal control or administrative issues.
- Risk of delisting from Nasdaq if compliance is not regained by the extended deadline.
- The CEO is also serving as the Interim CFO, which may indicate resource constraints or management instability.
📋 Key Facts
- Received delinquency notification from Nasdaq on August 21, 2026.
- Non-compliance is due to failure to file Form 10-Q for the period ended June 30, 2026.
- Deadline to submit a compliance plan to Nasdaq is October 20, 2026.
- If a plan is accepted, the company may receive an extension until February 16, 2027, to regain compliance.
- The company's common stock (BRTX) continues to trade on the Nasdaq Capital Market for now.
BioRestorative Therapies, Inc. has immediately suspended all orders and shipments of its ExoCR and BioX biocosmeceutical product lines pending a business review and regulatory assessment. The company is currently reviewing documentation, sourcing, and the regulatory status of these products.
🚩 Red Flags
- Immediate suspension of primary revenue-generating product lines (ExoCR and BioX).
- Regulatory uncertainty regarding sourcing and documentation for existing products.
- Potential total loss of biocosmeceutical business segment if regulatory issues are not resolved.
- Forward-looking statements explicitly mention the 'need for additional capital' as a risk factor.
📋 Key Facts
- Effective August 7, 2026, all orders and shipments for ExoCR and BioX product lines are suspended.
- The suspension is pending a business review and regulatory assessment regarding documentation, sourcing, and regulatory status.
- The company has not yet decided whether to discontinue the affected product lines.
- CEO Katharyn Field serves as both President and Interim CFO.
BioRestorative Therapies faces significant leadership instability following the resignations of its CEO, CFO, and a Director. The departures are accompanied by legal disputes regarding 'Good Reason' severance claims totaling $2.85 million and an internal investigation into executive employment agreement amendments.
🚩 Red Flags
- Mass exodus of C-suite executives (CEO and CFO) simultaneously.
- Legal dispute/disagreement between management and the Board regarding 'Change in Control' definitions.
- Board has launched an investigation into the negotiation and execution of executive employment amendments.
- Resignation of a Director without stated reason (though company claims no disagreement).
- Potential for significant cash outflow ($2.85M) via contested severance claims.
📋 Key Facts
- CEO Lance Alstodt resigned effective July 13, 2026, asserting 'Good Reason' based on a claimed Change in Control.
- CFO Robert Kristal resigned effective July 13, 2026, also asserting 'Good Reason'.
- Director David Rosa resigned from the Board and all committees effective July 11, 2026.
- The Company is disputing the validity of the 'Good Reason' claims and has withheld severance payments pending an internal investigation by special counsel.
- Katharyn Field appointed as interim CEO and interim CFO/Treasurer/Secretary on July 13, 2026.
- Potential aggregate cash severance liability of approximately $2.85 million if resignations are deemed valid.
BioRestorative Therapies, Inc. filed an 8-K to announce its third quarter financial results for the period ended September 30, 2025. The filing serves as a vehicle to furnish a press release containing business updates and earnings data.
📋 Key Facts
- Reporting period: Third Quarter ended September 30, 2025.
- Filing date: November 12, 2025.
- The filing includes a press release (Exhibit 99.1) containing financial results and a business update.
- A conference call was scheduled to discuss the third quarter results.
BioRestorative Therapies, Inc. entered into subscription agreements for a registered direct offering and a concurrent private placement of unregistered warrants to raise approximately $1.085 million in gross proceeds.
🚩 Red Flags
- Significant dilution potential due to the issuance of 678,125 new shares and 508,592 warrant shares.
- Warrants include a cashless exercise option which can further dilute existing shareholders.
- The offering is relatively small ($1.085M), suggesting limited runway for a biotech company.
📋 Key Facts
- Registered Direct Offering: 678,125 shares of common stock at $1.60 per share.
- Private Placement: Unregistered warrants to purchase up to 508,592 shares at an exercise price of $2.75 per share.
- Gross proceeds expected to be $1.085 million (before fees and expenses).
- Placement Agent: Alere Financial Partners; cash fee of 6% for introduced investors and 4% for others, plus a warrant covering up to 6% of shares sold.
- Use of proceeds: Clinical trials for BRTX-100, ThermoStem Program R&D, biocosmeceuticals platform development, and working capital.
- Expected closing date: On or about October 8, 2025.
BioRestorative Therapies, Inc. held its Annual Meeting of Stockholders on September 18, 2025. The meeting resulted in the election of Class II directors and approval of several key corporate matters including an amendment to the stock incentive plan.
🚩 Red Flags
- High number of broker non-votes (over 3.3 million shares) across multiple items suggests significant uninstructed or non-voting institutional/retail positions, though common in micro-caps with high retail interest or complex structures.
📋 Key Facts
- Annual Meeting held on September 18, 2025.
- Elected Francisco Silva and David Rosa as Class II directors.
- Approved amendment to the 2021 Stock Incentive Plan, increasing authorized shares from 6,850,000 to 9,850,000.
- Ratified CBIZ CPAs P.C. as independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Approved executive officer compensation on a non-binding advisory basis.
BioRestorative Therapies, Inc. has released an updated corporate presentation to be used for investor meetings and conferences. The information was furnished under Item 7.01 of Form 8-K and is not considered filed material.
📋 Key Facts
- Company released an updated corporate presentation on August 14, 2025.
- The presentation is intended for use at conferences and investor meetings.
- Information was furnished under Item 7.01 (Regulation FD Disclosure) rather than filed as material information.
BioRestorative Therapies, Inc. filed an 8-K to announce its second quarter financial results for the period ended June 30, 2025. The filing serves as a vehicle to furnish a press release containing business updates and earnings data.
📋 Key Facts
- Company announced Q2 2025 financial results on August 12, 2025.
- The filing includes a business update alongside the financial results.
- A conference call was scheduled to discuss the quarterly results.
BioRestorative Therapies, Inc. issued an 8-K to furnish preliminary clinical data from its Phase 2 trial of BRTX-100 for chronic lumbar disc disease (cLDD). The data was presented by the VP of R&D at the ISSCR 2025 Annual Meeting in Hong Kong.
📋 Key Facts
- Presented preliminary, blinded clinical safety and feasibility data from approximately 30 patients.
- Trial subject: Phase 2 trial of BRTX-100 for chronic lumbar disc disease (cLDD).
- Presentation occurred at the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting (June 11-14, 2025).
- Data involves intradiscal injections of hypoxic cultured mesenchymal stem cells.
BioRestorative Therapies, Inc. filed an 8-K to announce the release of its financial results and a business update for the first quarter ended March 31, 2025.
📋 Key Facts
- The filing announces the issuance of Q1 2025 financial results (ended March 31, 2025).
- A press release containing a business update was issued on May 14, 2025.
- The company scheduled a conference call to discuss the quarterly results and business developments.
BioRestorative Therapies, Inc. announced the resignation of its independent auditor, Marcum LLP, and the appointment of CBIZ CPAs P.C. as its new independent registered public accounting firm effective April 16, 2025.
🚩 Red Flags
- Auditor change (Marcum LLP resigned)
- Going concern language in the 2024 fiscal year report
- Material weaknesses identified in internal control over financial reporting for two consecutive years
- Reportable events regarding lack of effective controls over accounting for warrants and journal entries
📋 Key Facts
- Marcum LLP resigned as the Company's independent auditor on April 16, 2025.
- CBIZ CPAs P.C. has been engaged by the Audit Committee to replace Marcum LLP.
- The fiscal year ended December 31, 2024 report included an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern.
- The Company reported material weaknesses in internal control over financial reporting for FY2023 and FY2024.
- Material weaknesses include lack of adherence to formal policies, inadequate risk assessment procedures, and ineffective controls over journal entries, account reconciliations, income taxes, and warrant accounting.
BioRestorative Therapies, Inc. announced the upcoming release of its financial results for the fiscal year ended December 31, 2024. The company will host a conference call to review these results and provide a business update.
📋 Key Facts
- Financial results for the year ended December 31, 2024, to be released after market close on March 27, 2025.
- Management will host a conference call to review financial performance and provide a business update.
- The filing includes an announcement of a press release (Exhibit 99.1) regarding the results.
BioRestorative Therapies, Inc. filed an 8-K to disclose a presentation made by its VP of Research and Development at the Orthopaedic Research Society (ORS) 2025 Annual Meeting. The filing serves as a Regulation FD disclosure regarding the use of presentation materials for future investor communications.
📋 Key Facts
- On February 8, 2025, Francisco Silva (VP of R&D) presented at the ORS 2025 Annual Meeting in Phoenix, Arizona.
- The company intends to use the presentation materials from the meeting for future business presentations to investors, lenders, and other stakeholders.
- Presentation materials will be available on the company's website under 'Scientific Publications' for a period of 90 days.
- Information is furnished under Item 7.01 (Regulation FD Disclosure) rather than filed.
BioRestorative Therapies, Inc. filed an 8-K to announce its third quarter financial results for the period ended September 30, 2024 and provided a business update. The filing also notes the presentation of preliminary clinical trial data for BRTX-100 at a medical symposium.
📋 Key Facts
- Announced Q3 2024 financial results (ended Sept 30, 2024).
- Presented preliminary 26 and 52 week blinded data from Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease.
- Data presentation occurred at the Orthopaedic Research Society (ORS) Philadelphia Spine Research Society (PSRS) Symposium on Nov 13, 2024.
BioRestorative Therapies, Inc. announced the upcoming presentation of preliminary 26–52 week blinded data from its Phase 2 clinical trial for BRTX-100 at a major spine research symposium. The company will also host a webcast on November 13, 2024, to discuss these results alongside Q3 2024 financial updates.
📋 Key Facts
- Preliminary 26–52 week blinded data from Phase 2 clinical trial of BRTX-100 (chronic lumbar disc disease) will be presented on November 13, 2024.
- Presentation to be delivered by Francisco Silva, VP of Research and Development, at the ORS/PSRS 7th International Spine Research Symposium.
- Company will hold a webcasted conference call and slide presentation on November 13, 2024, at 4:30 p.m. ET.
- The upcoming call will include a review of Q3 2024 financial results and a general business update.
BioRestorative Therapies, Inc. entered into a new $3.6 million At The Market (ATM) offering agreement with Rodman & Renshaw LLC. This follows the termination of a previous $6.1 million sales agreement with JonesTrading Institutional Services LLC.
🚩 Red Flags
- Continuous dilution: The company is replacing one equity offering mechanism with another to raise capital.
- Micro-cap financing pattern: Frequent use of ATM offerings often indicates a need for immediate working capital and can lead to significant shareholder dilution.
📋 Key Facts
- Entered into an At The Market Offering Agreement with Rodman & Renshaw LLC on November 6, 2024.
- Aggregate offering price for new shares is up to approximately $3.6 million.
- Agent (Rodman & Renshaw) will receive a 3.0% commission on gross sales proceeds.
- The company terminated its prior 'Capital on Demand' agreement with JonesTrading Institutional Services LLC on November 1, 2024.
- Under the prior agreement, the company had already sold $622,235 worth of common stock.
BioRestorative Therapies, Inc. held its Annual Meeting of Stockholders on September 19, 2024. The meeting resulted in the election of a Class I director, an amendment to increase authorized shares under the 2021 Stock Incentive Plan, and the ratification of Marcum LLP as the independent auditor.
🚩 Red Flags
- Significant increase in authorized shares under the Stock Incentive Plan (from 3.85M to 6.85M), which can lead to future dilution of existing shareholders.
📋 Key Facts
- Annual Meeting held on September 19, 2024.
- Nickolay Kukekov, Ph.D. elected as Class I director (2,050,111 shares 'For').
- Amendment to the 2021 Stock Incentive Plan approved to increase authorized shares from 3,850,000 to 6,850,000.
- Marcum LLP ratified as independent registered public accounting firm for fiscal year ending Dec 31, 2024.
BioRestorative Therapies, Inc. filed an 8-K to announce its financial results and business update for the second quarter ended June 30, 2024. The filing serves as a vehicle to furnish press release information regarding quarterly operations.
📋 Key Facts
- Report date: August 13, 2024
- Reporting period: Second Quarter ended June 30, 2024
- The company issued a press release (Exhibit 99.1) containing financial results and a business update.
- A conference call was scheduled to discuss the quarterly results.
BioRestorative Therapies, Inc. announced that its second quarter 2024 financial results will be released after market close on August 13, 2024. The company will also host a conference call to review the results and provide a business update.
📋 Key Facts
- Q2 2024 financial results release date: August 13, 2024 (after market close).
- Management will host a conference call following the release to discuss results and business updates.
- The filing is an announcement of upcoming earnings rather than the disclosure of the results themselves.
BioRestorative Therapies, Inc. received a notice from Nasdaq regarding non-compliance with listing rules due to the failure to file its Form 10-Q for the period ended March 31, 2024. The company is currently undergoing a restatement analysis which has delayed these filings.
🚩 Red Flags
- Delisting notice received from Nasdaq
- Failure to file periodic reports (Form 10-Q)
- Ongoing restatement analysis mentioned in the filing
- Risk of delisting if compliance is not regained by November 11, 2024
📋 Key Facts
- Received notice from Nasdaq on May 22, 2024, regarding delinquency in filing Form 10-Q for the period ended March 31, 2024.
- Non-compliance is specifically related to Nasdaq Listing Rule 5250(c)(1) (timely filing of periodic reports).
- The company has 60 days from the notice date to submit a plan of compliance to Nasdaq.
- Nasdaq may grant up to 180 days from the original due date (until November 11, 2024) to regain compliance.
- The delay is attributed to an ongoing restatement analysis.
BioRestorative Therapies, Inc. has determined that its previously issued financial statements for the years ended December 31, 2023, and certain quarters in 2022 and 2023 should be restated due to a misapplication of accounting guidance regarding warrant classification.
🚩 Red Flags
- Non-reliance on previously issued financial statements (Item 4.02) is a significant regulatory and accounting red flag.
- The error involves multiple tranches of warrants spanning several years, indicating potential historical weakness in internal controls over financial reporting.
📋 Key Facts
- The company concluded on May 23, 2024, that financial statements for the two years ended Dec 31, 2023, and quarters between March 31, 2022, and Sept 30, 2023, should no longer be relied upon.
- The restatement stems from a misapplication of ASC 815; warrants issued in November 2021 must be classified as liabilities rather than stockholders' equity.
- Warrants involved include 2,645,000 Public Warrants ($10.00 strike), 1,856,938 Private Warrants ($10.00 strike), and 235,970 Underwriter Warrants ($12.50 strike).
- The adjustments are non-cash in nature and do not impact cash, cash equivalents, investments, revenues, operating expenses, or loss from operations.
- The company targets filing an Amended Form 10-K for the year ended Dec 31, 2023, on or before June 28, 2024.
BioRestorative Therapies, Inc. announced its participation in the 36th Annual ROTH Conference scheduled for March 17-19, 2024. CEO Lance Alstodt is slated to participate in a fireside chat and present company materials.
📋 Key Facts
- Company will participate at the 36th Annual ROTH Conference (March 17-19, 2024) in Dana Point, California.
- CEO Lance Alstodt is scheduled for a fireside chat during the event.
- The company provided presentation materials as Exhibit 99.2.
BioRestorative Therapies, Inc. entered into agreements to facilitate the exercise of existing warrants at a reduced price in exchange for new warrants. The transaction is expected to generate approximately $8.1 million in gross proceeds to fund clinical trials and R&D.
🚩 Red Flags
- Significant dilution: The issuance of up to 2.5 million new warrants at a $2.43 strike price represents substantial potential future dilution for existing shareholders.
- Reduced exercise price: Lowering the exercise price of existing warrants is often a sign of liquidity pressure or a need to incentivize holders to provide immediate cash.
📋 Key Facts
- Existing Warrants (3,351,580 shares) will be exercised at a reduced price of $2.33 per share.
- New Warrants will be issued for up to 2,513,685 shares at an exercise price of $2.43 per share.
- The New Warrants have a five-year term and require a payment of $0.125 per share.
- Total gross proceeds from the transaction are approximately $8.1 million before advisory fees.
- Roth Capital Partners, LLC will receive a cash fee of approximately $528,000 for financial advisory services.
- Proceeds are earmarked for BRTX-100 clinical trials, ThermoStem Program R&D, and general working capital.
BioRestorative Therapies, Inc. issued an 8-K to announce the presentation of clinical data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting. The disclosure focuses on preliminary Phase 2 safety and feasibility data for its lead candidate, BRTX-100.
📋 Key Facts
- Presented a poster titled 'Autologous Stem Cell Therapy for Chronic Lumbar Disc Disease' at the ORS 2024 Annual Meeting on February 4, 2024.
- Data covers preliminary 26–52 week blinded results from an ongoing Phase 2 clinical trial of BRTX-100.
- The data pertains to intradiscal injections of Hypoxic Cultured Mesenchymal Stem Cells for subjects with chronic lumbar disc disease.
- Information was furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.
BioRestorative Therapies, Inc. announced the upcoming presentation of preliminary 26–52 week blinded data from its Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease at the ORS 2024 Annual Meeting.
📋 Key Facts
- Preliminary 26–52 week blinded data from Phase 2 clinical trial of BRTX-100 to be presented.
- Data pertains to subjects with chronic lumbar disc disease.
- Presentation scheduled for the Orthopaedic Research Society (ORS) 2024 Annual Meeting (Feb 2-6, 2024).
- Webcasted conference call and slide presentation scheduled for February 5, 2024, at 8:30 a.m. ET.